Klivira
Request demo

Navigating Anthem (Elevance Health) Fasenra Prior Authorization

Successfully managing Anthem (Elevance Health) Fasenra prior authorization requests is critical for timely patient access to this essential biologic for severe eosinophilic asthma.

For revenue cycle directors and prior authorization coordinators, navigating the specific requirements for high-cost specialty drugs like Fasenra with complex payers like Anthem presents ongoing challenges. Understanding Anthem's submission channels, medical policies, and PBM processes is key to minimizing denials and accelerating patient care.

Fasenra: A Target for Prior Authorization Scrutiny

Fasenra (benralizumab) is an interleukin-5 (IL-5) receptor antagonist indicated as an add-on maintenance treatment for severe eosinophilic asthma in patients 12 years and older. As a high-cost biologic, it consistently requires prior authorization (PA) across commercial, Medicare Advantage, and Medicaid managed care plans, including those administered by Anthem.

Anthem's Prior Authorization Channels for Specialty Drugs

For specialty injectable medications like Fasenra, Anthem-licensed plans typically route prior authorization through their medical benefit review processes. Submissions are primarily facilitated via Availity Essentials, Anthem's multi-payer provider workspace, which supports PA initiation, member benefit lookup, and document uploads. X12 278 electronic transactions are also accepted through clearinghouses for medical benefit prior authorizations.

Understanding Anthem's Fasenra Medical Policies and Formulary

Anthem operating companies publish specific medical policies and clinical utilization management guidelines for specialty drugs, accessible through provider sites via Availity. These policies outline the medical necessity criteria, step therapy requirements, and appropriate dosing for Fasenra. While Fasenra is primarily a medical benefit drug, Anthem's in-house PBM, CarelonRx (formerly IngenioRx), manages the broader pharmacy benefit and may influence formulary placement or specific requirements for specialty medications.

Key Considerations for Anthem Fasenra PA Submissions

  • Medical Necessity Documentation: Provide comprehensive clinical notes supporting severe eosinophilic asthma diagnosis and failed prior therapies.
  • Step Therapy Adherence: Confirm compliance with Anthem's required step therapy protocols, which may include inhaled corticosteroids and long-acting beta-agonists.
  • Eosinophil Count: Document baseline eosinophil counts as per Anthem's medical policy criteria.
  • Site-of-Service: Be aware of potential site-of-care policies for injectable medications, a common Anthem pattern.
  • Policy Versioning: Reference the specific Anthem state-plan medical policy number and effective date.

Navigating Denials and Appeals for Fasenra with Anthem

Common denial reasons for Fasenra with Anthem include insufficient documentation of medical necessity, failure to meet step therapy requirements, or non-adherence to site-of-service policies. Denials are typically communicated via X12 277/835 transactions or Availity status updates. Appeals for standard medical benefit prior authorizations follow the Anthem operating company's documented appeals process, with peer-to-peer review options available to discuss clinical rationale.

Klivira's Role in Streamlining Anthem Fasenra PA

Klivira automates the complex prior authorization workflow for specialty drugs like Fasenra across Anthem's diverse submission channels. By integrating directly with EMRs and payer portals, Klivira streamlines documentation gathering, submission via X12 278 and Availity, and status tracking, reducing manual effort and accelerating decision times for Anthem Fasenra requests.

Frequently asked questions

Which Anthem entity handles Fasenra prior authorizations?

Prior authorizations for Fasenra, as a medical benefit injectable, are managed by the specific Anthem operating company for your state. Submissions route through Availity Essentials or via X12 278, aligning with the medical policy framework of Elevance Health, Anthem's corporate parent.

Is Fasenra typically covered under the medical or pharmacy benefit by Anthem?

Fasenra is generally covered under the medical benefit for Anthem-licensed plans due to its administration as a specialty injectable. However, it's crucial to verify the specific member's plan benefits and the current Anthem medical policy, as the medical/pharmacy benefit split for specialty drugs can be therapeutic-category specific.

Where can I find Anthem's medical policy for Fasenra?

Anthem's medical policies and clinical utilization management guidelines for specialty drugs like Fasenra are published on their provider websites, typically accessible through Availity. You should search for the specific policy number and ensure it corresponds to the member's state-licensed Anthem plan and effective date.

What are common reasons for Fasenra prior authorization denials from Anthem?

Common denial reasons for Fasenra with Anthem include insufficient clinical documentation to support medical necessity, failure to complete required step therapy, or not meeting specific eosinophil count criteria. Site-of-service mismatches can also lead to denials for injectable medications.

Does Anthem support electronic prior authorization (ePA) for Fasenra?

Yes, Anthem-licensed plans accept X12 278 transactions for medical benefit prior authorizations, which would apply to Fasenra. Elevance Health has also participated in Da Vinci Project initiatives to advance electronic PA capabilities. For pharmacy benefit drugs, CoverMyMeds and Surescripts ePA are utilized by CarelonRx.

Related coverage

Other fasenra prior authorization by payer

Other fasenra prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo